Ryan Zimmerman, an analyst from BTIG, maintained the Buy rating on Alcon. The associated price target is $91.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan Zimmerman has given his Buy rating due to a combination of factors including Alcon’s strategic initiatives and market opportunities. The company has launched a head-to-head clinical trial to compare its SYSTANE PRO product with Bausch + Lomb’s MIEBO, aiming to establish its efficacy in treating evaporative dry eye disease. This trial is expected to bolster Alcon’s clinical evidence and enhance its competitive position in the dry eye market, which is sizable and growing.
Additionally, Alcon’s valuation is appealing, with a price target based on a multiple that is a discount to its historical average, suggesting potential for share price recovery. The company’s top-line growth and operating margin expansion are expected to improve as it progresses into the fiscal year 2026, further supporting the Buy rating.
In another report released on November 18, KeyBanc also reiterated a Buy rating on the stock with a $91.00 price target.